JP2024153803A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024153803A5 JP2024153803A5 JP2024123110A JP2024123110A JP2024153803A5 JP 2024153803 A5 JP2024153803 A5 JP 2024153803A5 JP 2024123110 A JP2024123110 A JP 2024123110A JP 2024123110 A JP2024123110 A JP 2024123110A JP 2024153803 A5 JP2024153803 A5 JP 2024153803A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- antibody
- cancer
- killing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026071352A JP2026126283A (ja) | 2015-06-24 | 2026-04-23 | Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562184018P | 2015-06-24 | 2015-06-24 | |
| US62/184,018 | 2015-06-24 | ||
| US201562249546P | 2015-11-02 | 2015-11-02 | |
| US62/249,546 | 2015-11-02 | ||
| US201562250566P | 2015-11-04 | 2015-11-04 | |
| US62/250,566 | 2015-11-04 | ||
| US201562263307P | 2015-12-04 | 2015-12-04 | |
| US62/263,307 | 2015-12-04 | ||
| US201662331489P | 2016-05-04 | 2016-05-04 | |
| US62/331,489 | 2016-05-04 | ||
| PCT/US2016/039165 WO2016210223A1 (en) | 2015-06-24 | 2016-06-24 | Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38 |
| JP2017566768A JP7041519B2 (ja) | 2015-06-24 | 2016-06-24 | Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療 |
| JP2022015442A JP7532428B2 (ja) | 2015-06-24 | 2022-02-03 | Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022015442A Division JP7532428B2 (ja) | 2015-06-24 | 2022-02-03 | Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026071352A Division JP2026126283A (ja) | 2015-06-24 | 2026-04-23 | Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024153803A JP2024153803A (ja) | 2024-10-29 |
| JP2024153803A5 true JP2024153803A5 (enExample) | 2025-03-18 |
| JP7856702B2 JP7856702B2 (ja) | 2026-05-11 |
Family
ID=57586547
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017566768A Active JP7041519B2 (ja) | 2015-06-24 | 2016-06-24 | Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療 |
| JP2022015442A Active JP7532428B2 (ja) | 2015-06-24 | 2022-02-03 | Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療 |
| JP2024123110A Active JP7856702B2 (ja) | 2015-06-24 | 2024-07-30 | Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療 |
| JP2026071352A Pending JP2026126283A (ja) | 2015-06-24 | 2026-04-23 | Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017566768A Active JP7041519B2 (ja) | 2015-06-24 | 2016-06-24 | Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療 |
| JP2022015442A Active JP7532428B2 (ja) | 2015-06-24 | 2022-02-03 | Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026071352A Pending JP2026126283A (ja) | 2015-06-24 | 2026-04-23 | Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療 |
Country Status (37)
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2551282A3 (en) * | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| KR102391731B1 (ko) | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| EP3122173B2 (en) | 2014-03-26 | 2024-05-29 | SCR Engineers Ltd | Livestock location system |
| PL3122781T3 (pl) | 2014-03-28 | 2020-06-15 | Xencor, Inc. | Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3 |
| US10986817B2 (en) | 2014-09-05 | 2021-04-27 | Intervet Inc. | Method and system for tracking health in animal populations |
| US11071279B2 (en) | 2014-09-05 | 2021-07-27 | Intervet Inc. | Method and system for tracking health in animal populations |
| WO2016040294A2 (en) | 2014-09-09 | 2016-03-17 | Janssen Biotech, Inc. | Combination therapies with anti-cd38 antibodies |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| HK1245171A1 (zh) | 2014-11-26 | 2018-08-24 | Xencor, Inc. | 结合cd3和cd38的异二聚体抗体 |
| JP6696982B2 (ja) | 2014-11-26 | 2020-05-20 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 |
| PE20171094A1 (es) | 2014-12-04 | 2017-08-07 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| CN107708734B (zh) | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| PT3370768T (pt) * | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| JP7027321B2 (ja) | 2015-11-03 | 2022-03-01 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体の皮下製剤及びその使用 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| EP3387013B1 (en) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| KR102543118B1 (ko) | 2016-05-27 | 2023-06-14 | 아게누스 인코포레이티드 | 항-tim-3 항체 및 이의 사용 방법 |
| CA3026151A1 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| WO2018002181A1 (en) | 2016-06-28 | 2018-01-04 | Umc Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| RU2019102008A (ru) | 2016-06-28 | 2020-07-28 | Ксенкор, Инк. | Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа |
| CA3052084A1 (en) * | 2017-01-09 | 2018-07-12 | Biomunex Pharmaceuticals | A polypeptide linker for preparing multispecific antibodies |
| IL268110B2 (en) * | 2017-01-26 | 2024-01-01 | Sangamo Therapeutics Inc | B-cell engineering |
| US11780930B2 (en) | 2017-06-08 | 2023-10-10 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| KR102770104B1 (ko) * | 2017-06-08 | 2025-02-21 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 조정 항체 |
| KR102770106B1 (ko) | 2017-06-08 | 2025-02-21 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 조정 항체 |
| EP3434692A1 (en) * | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| AU2018316521B2 (en) | 2017-08-16 | 2025-01-30 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| JP7299873B2 (ja) | 2017-08-16 | 2023-06-28 | ブラック ベルト セラピューティクス リミテッド | Ｃｄ３８抗体 |
| US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| KR20210011919A (ko) | 2018-04-17 | 2021-02-02 | 셀덱스 쎄라퓨틱스, 인크. | 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물 |
| CA3098122A1 (en) | 2018-04-22 | 2019-10-31 | Vence, Corp. | Livestock management system and method |
| MA53123A (fr) * | 2018-07-13 | 2021-05-19 | Genmab As | Thérapie à médiation par trogocytose utilisant des anticorps cd38 |
| EP3820900A1 (en) * | 2018-07-13 | 2021-05-19 | Genmab A/S | Variants of cd38 antibody and uses thereof |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| BR112021005525A2 (pt) * | 2018-09-27 | 2021-06-29 | Musc Foundation For Research Development | combinação farmacêutica para o tratamento de câncer |
| FR3086837B1 (fr) | 2018-10-03 | 2021-06-18 | Allflex Europe | Pince pour la manipulation d’un dispositif d’identification d’un animal et/ou de prelevement d’un tissu d’un animal comprenant des moyens de maintien a moyens d’actionnement deportes |
| US11864529B2 (en) | 2018-10-10 | 2024-01-09 | S.C.R. (Engineers) Limited | Livestock dry off method and device |
| CN113678135B (zh) | 2019-02-08 | 2025-12-19 | 奥尔弗莱克斯澳大利亚有限公司 | 牲畜位置的判定 |
| EP3921761B1 (en) | 2019-02-08 | 2024-09-18 | Allflex Australia Pty Ltd | Electronic animal identification tag reader synchronisation |
| BR112021015541A2 (pt) | 2019-02-08 | 2022-01-11 | Allflex Australia Pty Ltd | Leitor de etiqueta eletrônica de animal |
| US20200308297A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses |
| CN120501855A (zh) * | 2019-05-14 | 2025-08-19 | 赛诺菲-安万特美国有限责任公司 | 给予抗cd38抗体以治疗多发性骨髓瘤的方法 |
| US12409474B2 (en) | 2019-08-28 | 2025-09-09 | S.C.R. (Engineers) Limited | Devices for analysis of a fluid |
| MX2022008050A (es) | 2020-01-16 | 2022-07-27 | Genmab As | Formulaciones de anticuerpos anti cumulo de diferenciacion 38 (cd38) y usos de las mismas. |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| EP4149632A1 (en) | 2020-05-14 | 2023-03-22 | Xencor, Inc. | Heterodimeric antibodies that bind msln and cd3 |
| USD990063S1 (en) | 2020-06-18 | 2023-06-20 | S.C.R. (Engineers) Limited | Animal ear tag |
| IL275518B (en) | 2020-06-18 | 2021-10-31 | Scr Eng Ltd | An animal tag |
| USD990062S1 (en) | 2020-06-18 | 2023-06-20 | S.C.R. (Engineers) Limited | Animal ear tag |
| IL275812B (en) | 2020-07-01 | 2022-01-01 | Scr Eng Ltd | System and method for placing devices |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| WO2022099090A1 (en) * | 2020-11-06 | 2022-05-12 | Xencor, Inc. | Heterodimeric antibodies that bind tgfbrii |
| EP4250912A4 (en) | 2020-11-25 | 2024-05-22 | IdentiGEN Limited | SYSTEM AND METHOD FOR TRACKING MEMBERS OF AN ANIMAL POPULATION |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| EP4277930A1 (en) | 2021-01-14 | 2023-11-22 | MorphoSys AG | Anti-cd38 antibodies and their uses |
| IL280374B2 (en) | 2021-01-24 | 2023-11-01 | Scr Eng Ltd | System and method for controlling animal marking |
| IL280744A (en) | 2021-02-09 | 2022-09-01 | Scr Eng Ltd | A system and method for determining animal population welfare |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| CN116997570A (zh) * | 2021-03-01 | 2023-11-03 | 莫佛塞斯公司 | 用于治疗抗体介导的移植排斥的抗cd38抗体 |
| EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
| CA206812S (en) | 2021-04-08 | 2023-04-11 | Chevillot Sas | Tag applicator for animals |
| CA206747S (en) | 2021-04-08 | 2024-12-30 | Chevillot Sas | Tag applicator for animals |
| IL283741A (en) | 2021-06-03 | 2022-07-01 | Scr Eng Ltd | A system and method for estimating greenhouse gas emissions in an environment that houses animals |
| CN118139639A (zh) * | 2021-08-25 | 2024-06-04 | 拜格拉夫55公司 | 治疗与免疫抑制b细胞相关联的癌症的方法 |
| US20230330138A1 (en) * | 2022-04-14 | 2023-10-19 | Creative Medical Technologies, Inc. | Treatment of cartilage degeneration using myeloid suppressor cells and exosomes derived thereof |
| US12402596B2 (en) | 2022-05-03 | 2025-09-02 | S.C.R. (Engineers) Limited | Milk channel and feed inlet coupled thereto, and system and method for conserving wash fluid in a washing process for cleaning a milkmeter system |
| CN114805582B (zh) * | 2022-06-29 | 2022-10-04 | 上海恒润达生生物科技股份有限公司 | 抗Trop2纳米抗体及其用途 |
| US20250382378A1 (en) | 2022-10-31 | 2025-12-18 | Genmab A/S | Cd38 antibodies and uses thereof |
| WO2024126750A1 (en) * | 2022-12-15 | 2024-06-20 | F. Hoffmann-La Roche Ag | Methods for treating cancer |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| EP2330213A1 (en) | 2003-03-05 | 2011-06-08 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| JP4794301B2 (ja) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | 抗体の製造方法 |
| EP2915820A1 (en) | 2004-02-06 | 2015-09-09 | MorphoSys AG | Anti-CD38 human antibodies and uses therefor |
| EP2551282A3 (en) * | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| CN101287764B (zh) | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| WO2008073160A2 (en) * | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| PL2081595T3 (pl) * | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| EP2580243B1 (en) * | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| WO2014017966A1 (en) | 2012-07-24 | 2014-01-30 | Telefonaktiebolaget L M Ericsson (Publ) | Apparatus and method for dynamically selecting a random access response window value for use with random access procedures in a network |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US9486547B2 (en) * | 2012-11-05 | 2016-11-08 | Morphosys Ag | Radiolabelled antibody and uses thereof |
| CA2909952C (en) | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| US20140356318A1 (en) * | 2013-05-28 | 2014-12-04 | Israel Barken | Adoptive cell therapy with specific regulatory lymphocytes |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| EP3021866A4 (en) * | 2013-07-15 | 2017-02-22 | The Board of Trustees of the Leland Stanford Junior University | Medical uses of cd38 agonists |
| JP2016536361A (ja) * | 2013-11-06 | 2016-11-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物 |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| JP7382695B2 (ja) * | 2020-07-09 | 2023-11-17 | パーカーエンジニアリング株式会社 | 塗料ミスト捕集装置 |
-
2016
- 2016-06-24 EP EP16815351.8A patent/EP3313441B1/en active Active
- 2016-06-24 SI SI201631806T patent/SI3313441T1/sl unknown
- 2016-06-24 LT LTEPPCT/US2016/039165T patent/LT3313441T/lt unknown
- 2016-06-24 EA EA201890131A patent/EA037548B1/ru unknown
- 2016-06-24 JP JP2017566768A patent/JP7041519B2/ja active Active
- 2016-06-24 MD MDE20180463T patent/MD3313441T2/ro unknown
- 2016-06-24 HR HRP20240338TT patent/HRP20240338T1/hr unknown
- 2016-06-24 UA UAA201800631A patent/UA124799C2/uk unknown
- 2016-06-24 US US15/191,808 patent/US20160376373A1/en not_active Abandoned
- 2016-06-24 KR KR1020247032639A patent/KR20240150522A/ko active Pending
- 2016-06-24 CA CA3269717A patent/CA3269717A1/en active Pending
- 2016-06-24 MA MA71262A patent/MA71262A/fr unknown
- 2016-06-24 PT PT168153518T patent/PT3313441T/pt unknown
- 2016-06-24 CA CA2990620A patent/CA2990620A1/en active Pending
- 2016-06-24 FI FIEP16815351.8T patent/FI3313441T3/fi active
- 2016-06-24 EP EP24158614.8A patent/EP4385569A3/en active Pending
- 2016-06-24 SM SM20240127T patent/SMT202400127T1/it unknown
- 2016-06-24 DK DK16815351.8T patent/DK3313441T5/da active
- 2016-06-24 RS RS20240308A patent/RS65347B1/sr unknown
- 2016-06-24 PL PL16815351.8T patent/PL3313441T3/pl unknown
- 2016-06-24 ES ES16815351T patent/ES2982292T3/es active Active
- 2016-06-24 WO PCT/US2016/039165 patent/WO2016210223A1/en not_active Ceased
- 2016-06-24 KR KR1020187001612A patent/KR102713847B1/ko active Active
- 2016-06-24 PE PE2017002833A patent/PE20181090A1/es unknown
- 2016-06-24 MX MX2018000261A patent/MX2018000261A/es unknown
- 2016-06-24 CN CN201680048975.9A patent/CN107921120A/zh active Pending
- 2016-06-24 AU AU2016281717A patent/AU2016281717B2/en active Active
- 2016-06-24 MY MYPI2017704935A patent/MY193727A/en unknown
- 2016-06-24 HU HUE16815351A patent/HUE066300T2/hu unknown
- 2016-06-24 BR BR112017027990-8A patent/BR112017027990A2/pt not_active Application Discontinuation
-
2017
- 2017-12-11 IL IL256248A patent/IL256248A/en unknown
- 2017-12-14 PH PH12017502311A patent/PH12017502311A1/en unknown
- 2017-12-19 CL CL2017003275A patent/CL2017003275A1/es unknown
- 2017-12-20 NI NI201700170A patent/NI201700170A/es unknown
- 2017-12-21 DO DO2017000305A patent/DOP2017000305A/es unknown
- 2017-12-22 CO CONC2017/0013332A patent/CO2017013332A2/es unknown
- 2017-12-22 SV SV2017005607A patent/SV2017005607A/es unknown
- 2017-12-26 EC ECIEPI201784878A patent/ECSP17084878A/es unknown
- 2017-12-26 GT GT201700286A patent/GT201700286A/es unknown
-
2018
- 2018-01-08 MX MX2021012134A patent/MX2021012134A/es unknown
- 2018-01-08 MX MX2021012133A patent/MX2021012133A/es unknown
- 2018-01-23 ZA ZA2018/00476A patent/ZA201800476B/en unknown
-
2019
- 2019-12-13 CL CL2019003657A patent/CL2019003657A1/es unknown
-
2022
- 2022-02-03 JP JP2022015442A patent/JP7532428B2/ja active Active
-
2024
- 2024-07-30 JP JP2024123110A patent/JP7856702B2/ja active Active
-
2026
- 2026-04-23 JP JP2026071352A patent/JP2026126283A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chang et al. | Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells | |
| FI3313441T3 (fi) | Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla | |
| JP7717686B2 (ja) | キメラｃｄ３融合タンパク質と抗ｃｄ３ベースの二重特異性ｔ細胞活性化エレメントの複合発現 | |
| JP2021155431A5 (enExample) | ||
| Xu et al. | Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody | |
| Spear et al. | Strategies to genetically engineer T cells for cancer immunotherapy | |
| JP2020103301A5 (enExample) | ||
| Zhu et al. | Natural killer cell engagers: From bi‐specific to tri‐specific and tetra‐specific engagers for enhanced cancer immunotherapy | |
| FI3455259T3 (fi) | Anti-PD-1-vasta-aineiden ja sädehoidon yhdistelmä syövän hoitoon | |
| JP2023071889A (ja) | Ｔｉｇｉｔおよびｐｄ－１／ｔｉｇｉｔ結合分子 | |
| JP2019536430A5 (enExample) | ||
| JP2016528195A5 (enExample) | ||
| JP2019519499A5 (enExample) | ||
| JP2018531939A (ja) | 治療用化合物及び方法 | |
| JP6578604B2 (ja) | 固形がんの治療剤 | |
| CN110511278A (zh) | 抗b7-h6抗体、融合蛋白及其使用方法 | |
| JP2021513540A5 (enExample) | ||
| JP2022532490A5 (enExample) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| KR20200092302A (ko) | 다중-특이적 항체 및 이들의 제조 및 사용 방법 | |
| JP2021510736A5 (enExample) | ||
| JP7689200B2 (ja) | 抗ｃｎｔｎ４特異的抗体及びその使用 | |
| JP2024016024A5 (enExample) | ||
| KR20190140756A (ko) | 자연 살상 세포에 결합하는 이중특이적 항체 및 이의 용도 | |
| Valent et al. | Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: perspectives and open issues |